Crossmark

Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study

Crossref DOI link: https://doi.org/10.1186/s13613-022-01017-5

Published Print: 2022

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Scharf, Christina

Weinelt, Ferdinand

Schroeder, Ines

Paal, Michael

Weigand, Michael

Zoller, Michael

Irlbeck, Michael

Kloft, Charlotte

Briegel, Josef

Liebchen, Uwe https://orcid.org/0000-0002-4375-0923
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03985605 at ClinicalTrials.gov

Documents that mention this clinical trial

Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
https://doi.org/10.1186/s13613-022-01017-5
Funding

Funding for this research was provided by:

Medizinischen Fakultät, Ludwig-Maximilians-Universität München (FöFoLe No. 002)

Universitätsklinik München
License Information

Text and Data Mining valid from 2022-01-01

Text and Data Mining valid from 2022-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-022-01017-5

Content Type: article

Copyright: Copyright © 2022 The Author(s) 2022. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below